- Home
- URG vs ZURA Comparison
URG vs ZURA Comparison
Compare URG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URG | ZURA |
|---|---|---|
| Founded | 2004 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.4M | 521.8M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | URG | ZURA |
|---|---|---|
| Price | $1.72 | $5.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $2.57 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 7.0M | 633.2K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,207,000.00 | N/A |
| Revenue This Year | $200.42 | N/A |
| Revenue Next Year | $98.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $0.99 |
| 52 Week High | $2.35 | $7.25 |
Technical Indicators
Market Signals| Indicator | URG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 42.90 |
| Support Level | $1.47 | $5.35 |
| Resistance Level | $1.74 | $5.75 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 68.10 | 28.84 |
Price Performance
Historical ComparisonAbout URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.